← Leaderboards
Masayuki Kuraoka
Boston Children'S Hospital
$2,004,966
Attributed
$2,917,882
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,917,882 · 4
By mechanism
R01$1,825,832 · 1
P01$1,092,050 · 3
Top collaborators
- Betsy C. Herold3 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Judy Lieberman$53,446,005
- Michael R. Farzan$72,884,755
- Sallie R. Permar$59,901,483
- Stephen C Harrison$48,000,876
- Paul Glyndwr Thomas$37,622,980
Others in their field
Other Rising Stars on “Immunoglobulin G”
- Jeff T Hutchins · Inhalon Biopharma, Inc.$5,672,575
- Christopher W Peterson · Fred Hutchinson Cancer Center$3,006,188
- Jacob Glanville · Centivax Inc$2,987,953
- Jennifer K Hoffman · Duke University$2,964,074
- Anna-Sophie Rommel · Icahn School Of Medicine At Mount Sinai$2,848,362
- Michael P Weiner · Abbratech, Inc.$2,709,380
Research focus
Immunoglobulin GGenerationsVaccine DevelopmentInfectionB-LymphocytesCellsImmune ResponseResponseAntibodiesVaccinesAntibody-Dependent Cell CytotoxicityAcuteBindingBiological MarkersExhibitsFemaleEbola VirusCytolysisAccelerationDoseComplementCongenicEngineeringClinical Trials
Grant awards (6)
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$594,071
R01 · FY2025 · AI
Core D: Bmem Analysis Core$386,400
P01 · FY2025 · AI · contact PI
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$603,661
R01 · FY2024 · AI
Core D: Bmem Analysis Core$300,000
P01 · FY2024 · AI · contact PI
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$628,100
R01 · FY2023 · AI
Core D: Bmem Analysis Core$405,650
P01 · FY2023 · AI · contact PI